Keyphrases
Amyotrophic Lateral Sclerosis
100%
Randomized Clinical Trial
100%
Zilucoplan
100%
Placebo
62%
Disease Progression
25%
Platform Trials
25%
Amyotrophic Lateral Sclerosis Functional Rating Scale-revised
25%
Etiology
12%
Neuroinflammation
12%
Placebo Groups
12%
Randomized Double-blind
12%
Placebo-controlled
12%
Clinical Trials
12%
Disease Severity
12%
Neurodegenerative Diseases
12%
Complement Activation
12%
Trial Registration
12%
Active Substances
12%
Patient Benefit
12%
Outcome Analysis
12%
Riluzole
12%
Time Use
12%
Rate Ratio
12%
Resource Use
12%
Treatment-related
12%
Posterior Probability
12%
Investigational Product
12%
Disease Rate
12%
Stopping for Futility
12%
Early Stopping
12%
Edaravone
12%
Credible Interval
12%
Complement C5
12%
Probability of Superiority
12%
Platform Design
12%
Adaptive Platform
12%
Shared Parameter Model
12%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Clinical Trial
100%
Amyotrophic Lateral Sclerosis
100%
Zilucoplan
100%
Placebo
87%
Disease Exacerbation
25%
Clinical Trial
12%
Disease Severity
12%
Nervous System Inflammation
12%
Degenerative Disease
12%
Edaravone
12%
Complement Component C5
12%
Riluzole
12%
Diseases
12%